1 / 31

INVENTION TO STARTUP SOURCES OF FUNDING

INVENTION TO STARTUP SOURCES OF FUNDING. Trevor Moody – Frazier Healthcare Ventures Jens U. Quistgaard – LipoSonix, Inc. Overview. Observations on the current financial climate Sources of funding Exercise – potential sources and their attributes Quick case study: SonoSite, Inc.

dunne
Download Presentation

INVENTION TO STARTUP SOURCES OF FUNDING

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. INVENTION TO STARTUPSOURCES OF FUNDING Trevor Moody – Frazier Healthcare Ventures Jens U. Quistgaard – LipoSonix, Inc.

  2. Overview • Observations on the current financial climate • Sources of funding • Exercise – potential sources and their attributes • Quick case study: SonoSite, Inc. • Quick case study: LipoSonix, Inc. • Venture funding in depth • What is a venture capitalist? • Venture capital funding criteria • What has changed recently?

  3. World Market Conditions • “Fear” is high • Global credit crunch/recession • Uncertainty about size and extent of problem • Companies most affected have: • Operational leverage to GDP or • Balance sheet debt VSX Volatility Index Sept 2000- Sept 2008 Data courtesy of SV Life Sciences LLP

  4. Effect on Private Companies • Relatively limited impact on healthcare companies • Reduced access to public markets for exit or financing • Reduced availability of credit and increased financing costs • Potentially longer time period to exit and lower exit valuations

  5. Performance of Healthcare Indices • Health sector is driven by non-discretionary spending and therefore traditionally a safe haven at times of economic turmoil • U.S. healthcare indices have all outperformed the S&P500 over the last 12 months • S&P 500 down 30% • Medical device (DJUSMC) down 11% and biotech (NBI) down 10% • Healthcare services (IHI) down 17% due to HMOs’ reduced rates of growth, credit contraction and fears about reimbursement

  6. Performance of Healthcare Indices 12 month performance of US Healthcare indices to 5 October 2008 Data courtesy of SV Life Sciences LLP

  7. Healthcare Fundamentals Strong • Recession resistant characteristics: • Rapidly ageing population • ~10% of world population is over 65 • Rising incidence of chronic disease • Rising healthcare costs • US healthcare spending $2.3 trillion in 2007, $7000 per person • Healthcare spending outpaces overall economic growth and inflation • Regulation creates high barriers to entry • Globalization and new markets • Innovation creates new markets Forecast rise in chronic disease 2003-2023 Predicted population growth 19% Data courtesy of SV Life Sciences LLP

  8. Healthcare Investing (USA) Equity into US VC-backed healthcare companies Pro-forma Data courtesy of SV Life Sciences LLP

  9. So… • Financial markets are a mess • Healthcare is a great place to be in these times • Funding is still available, but… • Bar is raised for new investments • Valuations are down • Each type of funding is affected differently

  10. Sources of Funding • What are they? • Self • Friends & Family • Debt • Grants, contracts – NIH, SBA, DARPA, etc. • Angels • Venture funds • Crossover funds • Strategic (other companies) • Public markets

  11. Sources of Funding • What are they? • Self • Friends & Family • Debt • Grants, contracts – NIH, SBA, DARPA, etc. • Angels • Venture funds • Crossover funds • Strategic (other companies) • Public markets

  12. Quick Case – SonoSite, Inc. • ATL Ultrasound – parent • Digital ultrasound pioneer • Core competence in ASIC implementation • The hand-carried ultrasound vision • The internal funding reality • DARPA dual-use program • ATL Ultrasound • University of Washington • VLSI Technology • Harris Semiconductor

  13. SonoSite – Getting Off the Ground • Basic development 1996-1997 • $12.6MM DARPA matching grant • Handheld Systems Business Group 1997 • Spin-out as SonoSite, Inc. - April 1998 • $17MM cash (+$13MM later) • Technology license • NASDAQ listed – distributed to ATL shareholders • First working prototype – September 1998 • First follow-on financing – April 1999 ($33.8MM)

  14. SonoSite – Lessons Learned • Government grants are a wonderful thing • But… • You need an impressive consortium to get large $ • There are some complications • Government technology rights • Consortium member’s technology rights • Reporting requirements • Etc… • Being a pre-revenue public company, in my humble opinion, is not a wonderful thing

  15. Quick Case – LipoSonix, Inc. • Originally pitched to investors by two individuals • Not successful • Picked up by a medical technology “incubator” • LipoSonix, Inc. founded in late 1999 • Initial venture funding, January 2001 (1.4MM) • IP licensing • Exploratory work • Series-B, tranche #1, November 2001 ($4MM) • More exploratory work

  16. LipoSonix – The Bothell Story • First full-time employee and dedicated facility, August – October 2002 • Series-B, tranche #2, September 2002 ($5.9MM) • First human study, July 2003 • The joy of venture debt • Series-C, July 2004 ($27.0MM) • More debt… • Initial customer shipment • More debt… • Acquired by Medicis Pharmaceutical Corp., July 2008

  17. LipoSonix – Lessons Learned • Top-drawer investors really help! • Be aware of capital structure issues associated with incubators • Be aware of capital structure and terms issues associated with venture financing • Multiples requirements • Liquidation preferences (!) • Etc… • Venture debt is a wonderful thing • If you can get it, and use it appropriately

  18. Different money sources are likely to be involved as the company grows

  19. 100% 60% 45% 25% 15% 10% 5% Funding needs increase significantly as the start-up moves towards commercialization Typical Funding Requirements Through a Company Lifecycle Confidential

  20. Sources of Funding – Venture Capital • What is a Venture Capitalist? • What criteria do VCs use to decide what to invest in? • What has changed recently?

  21. What is a Venture Capitalist? Follow the Money Investments in US Healthcare Portfolio Companies The General Partner And the Fund Sources of Capital • Retirement funds • University endowments • Families / high net worth individuals • General partners Update!

  22. What is a Venture Capitalist? • Typically small partnerships made up of a few General Partners (2-10) and other staff • General partners collect a percentage of the profits • Payouts over several years • Lucrative but high risk • Manage one or more funds raised sequentially over several years • Fund sizes range from <$5MM to >$2B • Some firms have been around for >50 years but vast majority have emerged in the last 15 years

  23. Medical Device VCs are looking for the most exciting new technologies A typical large healthcare VC may see 1000-2000 plans per year and invest in only 10 • Opportunities of great interest to medical device companies • Innovations that will be rapidly adopted by physicians • Incremental improvements • “Products, not companies”

  24. The Medical Device Investor’s checklist • Management / Founder Teams • Big Markets / Rapid Adoption • Regulatory/Reimbursement pathway • Early Clinical Proof-of-Principle • Patents

  25. Management/Founder teams • Most startups won’t have a CEO who has taken 3 companies public • Experience in other successful ventures • Have recruited top-tier mentors, board members and advisors • Open to adding other great executives to the team • Deep understanding of the target market and technology • Just want money, don’t want a partner • Unrealistic expectations of how hard it will be • Looking for a quick win

  26. Big markets/Rapid adoption • A very large existing or potential market is critical for generating investor interest • Physician specialty has demonstrated that they will rapidly adopt new technologies • $1B + potential market • Targeting procedurally oriented specialties e.g. cardiologists, orthopedic surgeons, etc • Challenging physician referral patterns • Requirement for large upfront capital outlays

  27. Regulatory/Reimbursement • FDA and CMS challenges are often underestimated by founders • Clear FDA approval requirements • Compelling economic argument to key decision makers e.g. physicians, hospitals • Physician community excited enough about technology to lobby for reimbursement • Trials requiring long follow-up • Great macro-economic argument but no-one incented to adopt

  28. Early Clinical Proof-of-Principle • A rapid path to clinical proof-of-principle greatly increases the fundability of a company • Rapid, ethical path to early clinical feasibility testing • Early clinical data that is highly suggestive of likely success of the pivotal trial • Need to run large, lengthy clinical trial to see if it works • Mediocre efficacy results

  29. Patents • Strong patent protection is essential in a technology-driven venture • Very strong protection around key innovation • Building a “patent thicket” to cover other related inventions • Broad early patents (an added bonus) • Sloppy patent strategy / disclosures that have limited patentability • Freedom to operate concerns

  30. What is the impact of the economic crisis on venture capital? • Limited impact in the short term – in 95% of cases, funds will continue • Quality VCs raise money from quality, long-term Limited Partners (LPs) • VCs have not typically used debt … fortunately • Potentially dramatic impact in the long term • Exits – Definitely delayed significantly • LP appetite for VC investments will decline over time • VC investment criteria will be more conservative • Early-stage VCs will still invest in early-stage companies but hurdles will increase • More sensitive on capital needs, time to market etc.

  31. Wrap-Up • Healthcare - Perhaps no better place to be driving innovation • Buyers less affected by acute economic turmoil • Insatiable demand • Demographics • Lot’s of money still out there … the bar is much higher but great opportunities and great teams will get funded • Take a strategic approach to fund raising. Target the best sources of money given your opportunity and stage of development • Expect to spend a lot of time raising money

More Related